Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 19/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005182 | 1.00 | MCHR1 (0.49) | MCHR1KCNH2ADRA1A | |
| SCHEMBL1001227 | 0.89 | MCHR1 (0.52) | MCHR1KCNH2ADRA1A | |
| SCHEMBL996584 | 0.89 | MCHR1 (0.52) | MCHR1KCNH2ADRA1A | |
| SCHEMBL996586 | 0.89 | MCHR1 (0.52) | MCHR1KCNH2ADRA1A | |
| SCHEMBL1002048 | 0.88 | MCHR1 (0.53) | MCHR1KCNH2ADRA1A | |
| SCHEMBL1002047 | 0.88 | MCHR1 (0.53) | MCHR1KCNH2ADRA1A | |
| SCHEMBL1001423 | 0.87 | MCHR1 (0.50) | MCHR1KCNH2ADRA1A | |
| SCHEMBL1002496 | 0.87 | MCHR1 (0.51) | MCHR1KCNH2ADRA1A | |
| SCHEMBL1002497 | 0.87 | MCHR1 (0.51) | MCHR1KCNH2ADRA1A | |
| SCHEMBL1002502 | 0.86 | MCHR1 (0.55) | MCHR1KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | BANYU PHARMACEUTICAL CO., INC. | 2011-01-20 | — | — | US | disclosed |
| EP-2272841-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTOR | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015198-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | MC1R, MCHR2, MCHR1 | MCHR1 3/4885KCNH2 2385/4885ADRA1A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.